Hetzer Roland, Stiller Brigitte
Department of Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Germany.
Nat Clin Pract Cardiovasc Med. 2006 Jul;3(7):377-86. doi: 10.1038/ncpcardio0575.
Mechanical circulatory support systems for the treatment of end-stage heart failure are now available for a wide variety of clinical situations and support times. Extracorporeal membrane oxygenation and centrifugal pump circuits have been most widely used in children, particularly in small infants. These systems are preferred for support after cardiac operations and for use in patients who have concomitant respiratory failure, but are suitable for short-term application only and intensive care is obligatory. True ventricular assist devices (VADs) qualify for long-term application and allow patients full mobilization. These features are important in patients awaiting heart transplantation as well as in those with myocarditis and cardiomyopathy, who might achieve complete cardiac recovery. Pneumatic pulsatile VADs have been available in pediatric sizes since 1992. At our institution, VAD use lasting from several days to 14 months in 70 infants and children with myocarditis and cardiomyopathy has led to a notable rise in survival in the past 5 years. We have been able to discharge 78% of the infants under 1 year old. In this review we present current VAD experience in children in the light of improvements in decision making, device technology, implantation techniques, and in coagulation monitoring and anticoagulation.
用于治疗终末期心力衰竭的机械循环支持系统现已适用于多种临床情况和支持时间。体外膜肺氧合和离心泵回路在儿童中应用最为广泛,尤其是在小婴儿中。这些系统在心脏手术后的支持以及伴有呼吸衰竭的患者中使用较为理想,但仅适用于短期应用,且必须进行重症监护。真正的心室辅助装置(VAD)适合长期应用,并允许患者充分活动。这些特点对于等待心脏移植的患者以及可能实现心脏完全恢复的心肌炎和心肌病患者非常重要。自1992年以来,气动搏动性VAD已有儿科尺寸可供使用。在我们机构,70例患有心肌炎和心肌病的婴儿和儿童使用VAD的时间从几天到14个月不等,在过去5年中显著提高了生存率。我们已能够使78%的1岁以下婴儿出院。在本综述中,我们根据决策制定、设备技术、植入技术以及凝血监测和抗凝方面的改进,介绍儿童目前使用VAD的经验。